| Revision as of 23:17, 13 November 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - updated 'ChemSpiderID_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacology...← Previous edit |
Revision as of 13:22, 16 December 2011 edit undoAnypodetos (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers39,350 editsm Disambig Humanize, replaced: humanized monoclonal antibody → humanized monoclonal antibody using AWBNext edit → |
| Line 47: |
Line 47: |
|
}} |
|
}} |
|
|
|
|
|
'''Tefibazumab''' (marketed under the brand name '''Aurexis''') is a ]d ] for the treatment of severe infections with '']''. Possible indications include the treatment of ''S. aureus'' in patient with ]<ref>{{ClinicalTrialsGov|NCT00198289}}</ref> and of ].<ref>{{pmid|18221183}}</ref> |
|
'''Tefibazumab''' (marketed under the brand name '''Aurexis''') is a ] for the treatment of severe infections with '']''. Possible indications include the treatment of ''S. aureus'' in patient with ]<ref>{{ClinicalTrialsGov|NCT00198289}}</ref> and of ].<ref>{{pmid|18221183}}</ref> |
|
|
|
|
|
It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal |author=John JF |title=Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection |journal=Curr. Opin. Mol. Ther. |volume=8 |issue=5 |pages=455–60 |year=2006 |pmid=17078388 |doi=}}</ref> |
|
It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal |author=John JF |title=Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection |journal=Curr. Opin. Mol. Ther. |volume=8 |issue=5 |pages=455–60 |year=2006 |pmid=17078388 |doi=}}</ref> |
